Preclinical Data Reported At European Hematology Association Congress

BERKELEY HEIGHTS, N.J., June 8, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced that Cyclacel scientists reported preclinical data supporting potential combinations of sapacitabine, a novel nucleoside analog, with novel targeted agents and other nucleoside analogs for the treatment of cancer. The combinations exploit sapacitabine's unique mechanism of action and were shown to be effective in models of leukemia and solid tumors. The data were presented at a poster presentation on Saturday, June 6 at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany.

"We are encouraged by the wide spectrum of anti-cancer agents that result in synergy when combined with sapacitabine. The EHA data extend previously reported data and support clinical evaluation of sapacitabine given with various anti-cancer agents as combination treatment for leukemia and other cancers," said Spiro Rombotis, President and CEO. "A week ago at the ASCO conference we reported interim Phase 2 data that pave the way for a pivotal trial of sapacitabine as a single agent in elderly patients with leukemia.